Author:
van der Noll Ruud,Jager Agnes,Ang Joo Ern,Marchetti Serena,Mergui-Roelvink Marja W. J.,Lolkema Martijn P.,de Jonge Maja J. A.,van der Biessen Diane A.,Brunetto Andre T.,Arkenau Hendrik-Tobias,Tchakov Ilian,Beijnen Jos H.,de Bono Johann S.,Schellens Jan H. M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference54 articles.
1. Lutterman Heeke A, Baker T, Lynce F, Pishvaian MJ, Isaacs C (2017) Prevalence of homologous recombination deficiency among all tumor types. J Clin Oncol 35(15 Suppl):abst 1502
2. Ashworth A (2008) A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790
3. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10:1192–1199
4. Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5:387–393
5. Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46:9–20
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献